Surgical mesh alert
This article was originally published in The Gray Sheet
Executive Summary
FDA warns physicians and consumers Oct. 20 about complications associated with surgical mesh devices to treat pelvic organ prolapse and stress urinary incontinence. The agency said it received more than 1,000 reports from nine manufacturers of problems with transvaginal placement of the mesh devices, including erosion through vaginal epithelium, infection, pain and urinary problems. Physicians should obtain specialized training in mesh placement techniques and monitor for complications, FDA advises. The agency also warned consumers about problems with surgical mesh for hernia repairs
You may also be interested in...
Regulatory News In Brief
Transvaginal surgical mesh scrutiny
Ethicon Exec: FDA Mesh Safety Notice Could Have Long-Term Impact
A manufacturer of surgical mesh devices for minimally invasive gynecological procedures is worried that a recent FDA safety alert may slow long-term adoption of the products even after better data is available
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”